Association of COVID-19 inflammation with activation of the C5a–C5aR1 axisJulien Carvelli, Éric Vivier, Marion Etiennot et al.|Nature|2020Cited by 555
Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE])*Julien Carvelli, Ferhat Meziani, Jean Dellamonica et al.|Critical Care Medicine|2022Cited by 29